Martin Ginis, Kathleen A. http://orcid.org/0000-0002-7076-3594
van der Scheer, Jan W.
Todd, Kendra R.
Davis, Jennifer C.
Gaudet, Sonja
Hoekstra, Femke http://orcid.org/0000-0002-0068-652X
Karim, Mohammad Ehsanul http://orcid.org/0000-0002-0346-2871
Kramer, John L. K.
Little, Jonathan Peter
Singer, Joel
Townson, Andrea
West, Christopher R.
Funding for this research was provided by:
Gouvernement du Canada | Canadian Institutes of Health Research (#PJT-165903)
Article History
Received: 3 February 2020
Revised: 21 April 2020
Accepted: 22 April 2020
First Online: 14 May 2020
Change Date: 15 July 2020
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41393-020-0519-2
Compliance with ethical standards
:
: MEK has received consulting fees from Biogen and participated in Advisory Boards and/or Satellite Symposia of Biogen Inc. for studies related to Multiple Sclerosis. All other authors declare they have no conflict of interest.
: This study protocol has been approved by the Clinical Research Ethics Board (CREB) of the University of British Columbia. All participants will provide written informed consent before taking part in the study (also see “Eligibility screening and informed consent” above). The CREB will review any protocol modifications, followed by updating the trial registration. Protocol and informed consent modifications will be made available using Open Science Framework (https://osf.io/). Informed consents will be revisited with enrolled participants if protocol modifications occur. The CREB will review any requests for use of data in an ancillary study beyond the scope of this RCT that are not covered by the original ethics application.